Regenerex Pharma (RGPX) EBITDA (2010 - 2025)

Regenerex Pharma (RGPX) has 13 years of EBITDA data on file, last reported at -$786709.0 in Q3 2025.

• EBITDA for Q3 2025 came in at -$786709.0, down 204.47% year-over-year; the trailing twelve-month figure through Sep 2025 was -$2.7 million (down 164.81% YoY), and the FY2025 annual result was -$1.8 million, up 47.31% from the prior year.
• EBITDA declined to -$786709.0 in Q3 2025 per RGPX's latest filing, from -$633783.0 in the prior quarter.
• Over five years, EBITDA peaked at -$11688.0 in Q2 2021 and troughed at -$2.8 million in Q3 2023.
• A 5-year average of -$385269.5 and a median of -$199779.0 in 2023 frame the typical range for EBITDA.
• The sharpest annual moves came in 2023 and 2024: EBITDA slumped 12855.37% in 2023, then jumped 90.73% in 2024.
• A 5-year view of EBITDA shows it stood at -$61975.0 in 2021, then jumped by 53.04% to -$29102.0 in 2022, then plunged by 722.57% to -$239384.0 in 2023, then sank by 30.13% to -$311510.0 in 2024, then tumbled by 152.55% to -$786709.0 in 2025.
• Business Quant data shows RGPX's EBITDA at -$786709.0 in Q3 2025, -$633783.0 in Q2 2025, and -$1.0 million in Q1 2025.